Sunday, December 6th: 3:30 – 5:30 pm
Continuing in the area of interventional cardiology, this session will focus on trials enrolling patients with complex lesions. The recent publication of the ISCHEMIA trial results in April 2020, report no evidence that an initial invasive strategy was more effective that an initial conservative strategy in reducing the risk of ischemic CV events or death. However, a companion publication did report significant improvements in health status. Subsequently additional clinical benefits in certain subgroups have been reported. How do we sort through the results of this trial, does it provide more questions than answers? Where do we go from here?
This session will be chaired by Dr. George Dangas, and Dr. Michael Gibson. Dr. Dangas is Director of Cardiovascular Innovation at The Mount Sinai Hospital in New York, USA. Dr. Gibson is an interventional cardiologist, at the Beth Israel Deaconess Medical Center in Boston MA, USA, and the founder of PERFUSE, an academic research organization providing clinical trial management services.
This session will look at the impact of the ISCHEMIA results on the field, with a presentation from one of the key trial investigators, Dr. Sripal Bangalore of the New York University Grossman School of Medicine, in New York, USA. Since the trial findings were sensitive to the definition of myocardial infarction (MI) that was used, we will take a closer look at the true relevance of peri-procedural MIs. Other issues to be discussed are the role of left main PCI versus CABG, and optimal use of hemodynamic support. Joining our co-chairs are: Roxana Mehran (New York, USA), Sunil Rao (Durham, USA), and Holger Thiele (Leipzig, GER).
The session and the moderated multi-stake holders debate will include additional points of view from industry (Chuck Simonton, from Abiomed, USA, maker of the Impella heart pump), and regulatory representatives (Lydia Glaw from the US FDA).
Comments